CLINICAL_TRIALS
trial_result
· 2021-04-02
Clinical Trial Update: Safety and Efficacy of KPI-121 in Subjects With DED [Phase 3]
Summary
Phase 3 clinical trial update on KPI-121 for keratoconjunctivitis sicca assessing safety and efficacy.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Kala Pharmaceuticals, Inc. | Conditions: Kerato Conjunctivitis Sicca | Phase 3 | Status: COMPLETED | Results posted: 2021-04-02